Zai In-licenses KRAS Inhibitor from Mirati in $338 Million Deal
June 01, 2021 at 06:30 AM EDT
Shanghai 's Zai Lab in-licensed Greater China rights to adagrasib, a KRASG12C inhibitor, from Mirati (NSDQ: MRTX) of San Diego in a $338 million agreement. Mirati will receive a $65 million upfront payment and up to $273 million in milestones, plus royalties. Mirati has registration-enabling studies of the candidate underway in NSCLC and colorectal cancer. Last week, Amgen was approved for US launch of its KRAS inhibitor, a target that was once considered undruggable. More details.... Stock Symbols: (NSDQ: ZLAB; HK: 9688) (NSDQ: AMGN) Share this with colleagues: // //